Related Experiment Video

Updated: Jun 16, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K

Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals

Lorenzo D'Ambrosio1,2, Saskia Litière3, Silvia Stacchiotti4

  • 1Department of Oncology, University of Turin, Turin, Italy.

Cancer
|August 9, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.4K

Related Experiment Videos

Last Updated: Jun 16, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

Cancer·2026

Feasibility and activity of concurrent neoadjuvant chemotherapy and radiation therapy in patients with high-risk soft tissue sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.

Annals of surgery·2026

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

Cancer research·2026

European Organisation for Research and Treatment of Cancer (EORTC) 2025 Program for Early Career Investigators: Advancing Ideas into Clinical Research.

European journal of cancer (Oxford, England : 1990)·2026

Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.

Cancer·2026

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

Cancer·2026

Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study.

Cancer·2026

Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late-stage incidence end points and post-trial ongoing evaluation-The Peachtree Consensus.

Cancer·2026

Annual Report to the Nation on the Status of Cancer, featuring 21st century progress against lung cancer.

Cancer·2026

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

Cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us